Atlas Trials

A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin

Clinical trial NCT01482377 · COMPLETED

Trial details

NCT number
NCT01482377
Sponsor
Hoffmann-La Roche
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Neoplasms
Start date
2011-12-01
Primary completion
2016-02-01
Enrollment
145

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.